CSCO First Live Studio Discusses Current Status and Future Trends of Precision Diagnosis and Treatment for Rare Targets in NSCLC

Sep 17, 2025 18:07 CST Updated 18:07

Novartis

Drug Development and Manufacturing

Novartis Approval Code TML0054110-112901

Valid from 2025-09-15 to 2026-09-14

Expired materials shall be deemed null and void.

Write:Shirley

Review:Shirley

Typesetting: Zelda

Execution:Atai

This platform aims to provide more medical information to healthcare professionals. The content published on this platform cannot replace professional medical guidance in any way and should not be regarded as diagnostic or treatment advice. If such information is used for purposes other than understanding medical information, this platform assumes no related responsibility. The platform does not endorse the descriptions and viewpoints of the content it publishes. If there are copyright issues, we kindly request the rights holder to contact us, and we will address the matter promptly.